US$ 23.25
va glp 1 coverage GLP-1s and The Payer Predicament Does anybody have any insight
Description
H.TonneijckL.SmitsM

This divergence reflects their unique perspectives and priorities

doi: 10.1053/j.gastro.2021.12.248 43

Tardif I, Gunette L, Zongo A, Demers , Lunghi C

These are just two examples in a larger familysome versions are engineered to resist that DPP-4 enzyme that normally breaks down GLP-1 so that their effect is really prolonged, while others are derived from animals and closely resemble the human version
